Testosterone derivatives are neuroprotective agents in experimental diabetic neuropathy

Cell Mol Life Sci. 2007 May;64(9):1158-68. doi: 10.1007/s00018-007-7002-5.

Abstract

In this study we have assessed the effect of testosterone (T), dihydrotestosterone (DHT) and 5alphaandrostan-3alpha, 17beta-diol (3alpha-diol) therapies on diabetic neuropathy. Diabetes was induced in adult male rats by the injection of streptozotocin and resulted in decreased T and increased 3alpha-diol levels in plasma and in decreased levels of pregnenolone and DHT in the sciatic nerve. Moreover, a reduced expression of the enzyme converting Tinto DHT (i.e., the 5alpha-reductase) also occurs at the level of sciatic nerve, suggesting that the decrease of DHT levels could be due to an impairment of this enzyme. Chronic treatment for 1 month with DHT or 3alpha-diol increased tail nerve conduction velocity and partially counteracted the increase of thermal threshold induced by diabetes. Treatment with DHT increased tibial Na(+),K(+)-ATPase activity and the expression of myelin protein P0 in the sciatic nerve.DHT, 3alpha-diol and T reversed the reduction of intra-epidermal nerve fiber density induced by diabetes. These observations indicate that T metabolites can reverse behavioral, neurophysiological, morphological and biochemical alterations induced by peripheral diabetic neuropathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anabolic Agents / therapeutic use
  • Androstane-3,17-diol / therapeutic use
  • Animals
  • Diabetes Mellitus, Experimental / physiopathology*
  • Diabetic Neuropathies / prevention & control*
  • Dihydrotestosterone / therapeutic use*
  • Male
  • Neuroprotective Agents / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Testosterone / therapeutic use*

Substances

  • Anabolic Agents
  • Neuroprotective Agents
  • Dihydrotestosterone
  • Androstane-3,17-diol
  • Testosterone